表紙
市場調查報告書

關注市場分析:茲卡病毒

Market Spotlight: Zika virus

出版商 Datamonitor Healthcare 商品編碼 594575
出版日期 內容資訊 英文 26 Pages
商品交期: 最快1-2個工作天內
價格
關注市場分析:茲卡病毒 Market Spotlight: Zika virus
出版日期: 2020年02月14日內容資訊: 英文 26 Pages
簡介

本報告提供茲卡病毒的治療藥市場相關分析,疾病概要和患者數的變化、預測,目前的主要的調查治療方法,現在與開發中臨床實驗的進展與上市計劃,主要的治療藥的市場趨勢預測 (今後10年份),資本交易的動向等。

分析的要點

疾病的背景情況

治療方法

  • 疫苗
  • 治療藥

流行病學

開發平台上的醫藥品

授權合約、資產收購交易

  • GSK/NIH的'SAM'策略:茲卡病毒相關的成果獲得的可能性
  • Sanofi:與美軍共同的在非營利的茲卡病毒的研究

臨床實驗形勢

  • 贊助商數:各狀態
  • 贊助商數:各相位

相關分析

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0180743

This Market Spotlight report covers the Zika virus market, comprising key pipeline therapies, clinical trials, probability of success, epidemiology, and licensing and acquisition deals.

Key Takeaways:

The Zika virus was first reported in continental South America in Brazil in May 2015.

In February 2016, between 440,000 and 1,300,000 people were infected in Brazil. In the US, about 225 Zika virus cases were reported in August 2017.

In addition, 554 cases were reported in people infected through local mosquito-borne transmission. Furthermore, autochthonous Zika virus transmission was reported in 25 countries in the Americas, Africa, and Asia.

In 2016, it was estimated that there were between 508 and 1,778 imported cases in Europe, particularly in France, Portugal, and Italy.

The majority of industry-sponsored drugs in active clinical development for Zika virus are in Phase I, with just a single product in Phase II.

Therapies in development for Zika virus focus on the immune system, viral antigens, and RNA polymerase. Candidates comprise DNA vaccines such as the National Institutes of Health's Zika Virus Vaccine, GeneOne's GLS-5700, and Inovio's INO-A002; Moderna's mRNA vaccines; Themis Bioscience's recombinant viral vector vaccine; Imutex's AGS-v vaccine; hVIVO's AGS-v PLUS vaccine; Johnson & Johnson's Ad26.ZIKV.001 vaccine; Takeda's TAK-426 vaccine; Emergent BioSolutions' ZIKV-IG; Valneva's VLA 1601; and BioCryst's galidesivir, a broad-spectrum antiviral drug.

The overall likelihood of approval of a Phase I antiviral asset is 14.3%, and the average probability a drug advances from Phase III is 74.4%. Drugs, on average, take 8.7 years from Phase I to approval, compared to 9.0 years in the overall infectious disease space.

There have been seven licensing and asset acquisition deals involving Zika virus drugs during 2015-20. The exclusive 2017 agreement between Emergent BioSolutions and Valneva, worth $58.3m, for the global rights to Valneva's Zika vaccine technology and VLA 1601 was the largest deal.

All clinical trials for Zika virus have been in either Phase I or Phase II, with no Phase III trials to date.

The US leads in terms of the number of Zika virus clinical trials globally.

Inovio, GeneOne, and Emergent have two completed trials each in the Zika virus space.

Inovio leads industry sponsors with four clinical trials for Zika virus, followed by GeneOne and Sanofi.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Vaccines
  • Therapeutics

EPIDEMIOLOGY

PIPELINE DRUGS

KEY REGULATORY EVENTS

  • FDA Revokes Emergency Authorization On Ebola, Zika Tests
  • US FDA Greenlights First-In-Kind Diagnostics, Device

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • GeoVax Collaborates With Enesi Pharma On Needle-Free Vaccines

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

  • Figure 1: Recent epidemiological updates
  • Figure 2: Zika cases timeline
  • Figure 3: Overview of pipeline drugs for Zika virus in the US
  • Figure 4: Pipeline drugs for Zika virus, by company
  • Figure 5: Pipeline drugs for Zika virus, by drug type
  • Figure 6: Pipeline drugs for Zika virus, by classification
  • Figure 7: Probability of success in the Zika virus pipeline
  • Figure 8: Licensing and asset acquisition deals in Zika virus, 2015-20
  • Figure 9: Clinical trials in Zika virus
  • Figure 10: Top 10 drugs for clinical trials in Zika virus
  • Figure 11: Top 10 companies for clinical trials in Zika virus
  • Figure 12: Zika virus trial locations
  • Figure 13: Zika virus trials status
  • Figure 14: Zika virus trials sponsors, by phase

LIST OF TABLES

  • Table 1: Pipeline drugs for Zika virus in the US